Pharmaceutical News

Special Report

EXPERT VIEW: Fewer ‘pay-for-delay’ agreements are likely but they might not disappear altogether

EXPERT VIEW: Fewer ‘pay-for-delay’ agreements are likely but they might not disappear altogether

The pharmaceutical sector is still reeling from the latest fines imposed by the European Competition Commission as part of its crackdown on so-called ‘pay-for-delay’ agreements. As a result, such practices could be used less frequently in the future but they are unlikely to disappear altogether, according to patent and trade mark attorneys Withers & Rogers.

Therapy Area

Region

News from the web

Back to top